Optimized Epitope-Flanking Sequences Enhance Antigen Presentation and T-Cell Responses Following mRNA Vaccination
Cells · 2026
DOI: 10.3390/cells15191753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Marie-Pierre Hardy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada. Hauptthemen laut MEDLINE: Antigen Presentation, CD8-Positive T-Lymphocytes, RNA, Messenger, Vaccination. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioCanRx, Epitopea Inc., BioCanRx/Ovarian Cancer Canada.
Abstract (Originalsprache)
mRNA vaccines can encode multiple tumor antigens whose presentation ultimately depends on adequate intracellular processing. To evaluate the potential impact of epitope-flanking sequences, we compared the immunogenicity of two mRNA vaccines in the MC38 mouse model. Both vaccines coded for the same tumor-specific antigens (TSAs). The only difference between the two vaccines was the identity of the epitope-flanking amino acids. The vaccine encoding TSAs bordered by optimized flanking sequences (TSA-Opti) cleared established tumors and elicited robust CD8+ T-cell responses. In contrast, the vaccine encoding the same TSAs surrounded by natural flanking sequences (TSA-Nat) induced weaker responses and incomplete protection against tumor growth. Quantitative immunopeptidomics showed that TSA-Opti increased antigen presentation levels, providing a mechanistic link between flanking-sequence design and the enhanced magnitude, clonal diversity, and functionality of TSA-specific CD8+ T cells. TSA-Opti further promoted durable memory, conferring long-term protection against tumor rechallenge. These results identify epitope-flanking sequences as tunable design elements that control peptide–MHC I density and thereby shape the magnitude, clonal diversity, tissue localization, and durability of antitumor CD8+ T-cell immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada.
- Epitopea, Inc., Montréal, QC H3T 1J4, Canada.
- Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
- Cognate Biotechnology Research, Montréal, QC H2S 3H1, Canada.
- Department of Chemistry, Université de Montréal, Montréal, QC H2V 0B3, Canada.
- Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
ORCID-Profile: Marie-Pierre Hardy, Chantal Durette, Robin Minati, Assya Trofimov, Joel Lanoix, Jean-Philippe Laverdure, Pierre Thibault, Claude Perreault
Förderung
- BioCanRx
- Epitopea Inc.
- BioCanRx/Ovarian Cancer Canada
- Katelyn Bedard Bone Marrow Association
Zitieren
APA
Hardy, M. P., Ouellet-Lavallée, G., Thériault, C., Durette, C., Vincent, K., Minati, R., Caron, I., Trofimov, A., Lanoix, J., Laverdure, J. P., Thibault, P., & Perreault, C. (2026). Optimized Epitope-Flanking Sequences Enhance Antigen Presentation and T-Cell Responses Following mRNA Vaccination. Cells. https://doi.org/10.3390/cells15191753
Vancouver
Hardy MP, Ouellet-Lavallée G, Thériault C, Durette C, Vincent K, Minati R, et al. Optimized Epitope-Flanking Sequences Enhance Antigen Presentation and T-Cell Responses Following mRNA Vaccination. Cells. 2026. doi:10.3390/cells15191753
BibTeX
@article{Hardy2026,
author = {Hardy, Marie-Pierre and Ouellet-Lavallée, Gabriel and Thériault, Catherine and Durette, Chantal and Vincent, Krystel and Minati, Robin and Caron, Isabelle and Trofimov, Assya and Lanoix, Joel and Laverdure, Jean-Philippe and Thibault, Pierre and Perreault, Claude},
title = {Optimized Epitope-Flanking Sequences Enhance Antigen Presentation and T-Cell Responses Following mRNA Vaccination},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15191753}
}
EUVIMED